← brief for 2026-08-11 · Slowing decline

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

Trial No results yet Not peer reviewed

Key takeaways

This new trial tests whether empagliflozin, a diabetes and kidney drug already used in adults, helps children and teens (ages 2 to 17) with chronic kidney disease. Children are randomly given the drug or a placebo (a dummy pill) to compare safety and effect. The trial is just opening, so there are no results yet.

Who did this work

Run by Boehringer Ingelheim.
Sites: University of Alabama at Birmingham · Phoenix Children's Hospital · University of California Los Angeles · Stanford University School of Medicine · University of California Davis · University of California San Francisco

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-08-07
https://clinicaltrials.gov/study/NCT07107945